Caladrius Biosciences Revenue and Competitors

Basking Ridge, NJ USA

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Caladrius Biosciences's estimated annual revenue is currently $9.8M per year.(i)
  • Caladrius Biosciences's estimated revenue per employee is $155,000

Employee Data

  • Caladrius Biosciences has 63 Employees.(i)
  • Caladrius Biosciences grew their employee count by 5% last year.

Caladrius Biosciences's People

NameTitleEmail/Phone
1
EVP R&D and CMOReveal Email/Phone
2
Director Clinical Affairs and ApheresisReveal Email/Phone
3
Staff AccountantReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$8.5M55-21%N/AN/A
#2
$0.2M10%N/AN/A
#3
$8.5M55-29%N/AN/A
#4
$108.5M5002%N/AN/A
#5
$0.8M50%N/AN/A
#6
$0.6M40%N/AN/A
#7
$14.7M68-23%$206.4MN/A
#8
$492.2M1503-15%$568MN/A
#9
$1.1M7-42%N/AN/A
#10
$4.5M290%N/AN/A
Add Company

What Is Caladrius Biosciences?

Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company with multiple technology platforms targeting select cardiovascular indications and autoimmune diseases.

keywords:N/A

N/A

Total Funding

63

Number of Employees

$9.8M

Revenue (est)

5%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Caladrius Biosciences News

2022-04-17 - Caladrius Biosciences (NASDAQ:CLBS) Receives New ...

Caladrius Biosciences (NASDAQ:CLBS) Receives New Coverage from Analysts at StockNews.com. Posted by admin on Apr 20th, 2022.

2022-04-13 - Caladrius Biosciences (NASDAQ:CLBS) & Marpai (NASDAQ ...

Caladrius Biosciences (NASDAQ:CLBS) & Marpai (NASDAQ:MRAI) Head-To-Head Comparison. Posted by admin on Apr 15th, 2022.

2022-04-06 - Caladrius Biosciences Treats First Patient in the Phase 1b ...

Caladrius Biosciences Treats First Patient in the Phase 1b Trial of CLBS201 for the Treatment of Diabetic Kidney Disease.

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$11.5M713%N/A
#2
$7.5M72-4%N/A
#3
$13.6M72N/AN/A
#4
$19.1M73-21%N/A
#5
$4.9M74-13%$145.5M